Home Cerebellar Brain Stimulation Study for Parkinson's Disease Symptoms
Tests mild cerebellar brain stimulation at home in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Key facts
- Where
- Brussels, BelgiumSee the site
Where in Belgium
- Hôpital ErasmeBrussels, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université Libre de Bruxelles
- Trial code
- NCT07548801
- Record updated
- 23 April 2026
- Original description
Background \& Rationale:Read full original descriptionShow less
Can Cerebellar Transcranial Direct Current Stimulation be Regarded as a Rational Therapeutic Option for Treating Parkinson's Disease ?
Background \& Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Inclusion: Patients with mild to moderate PD MDS-UPDRS part 1III or between 1 and 3 on Hoehn and Yahr score; Patients > 18 years of agE; Patients who have signed written informed consent.
Exclusion: Presence of an implanted electronic device (e.g., pacemaker, cochlear implants, deep brain stimulator); History of epileptic seizures; Active or past neurological condition affecting upper limb control (e.g., stroke, degenerative disease, tumor, traumatic sequelae), or any neuromuscular (e.g., upper limb polyneuropathy, myopathy) or orthopedic condition impairing upper limb motor control; Patients ≤ 18 years of age; Pregnant women; Presence of intracranial metallic hardware (e.g., vascular clips, orthopedic material); Subject unable to understand or perform the required motor tasks; Psychotropic polypharmacy (regular use of neuroleptics, anti-epileptics, benzodiazepines, etc.).